2126
COM:JWTHERAPEUTICS
JW Therapeutics
- Stock
Last Close
1.38
22/11 09:08
Market Cap
755.92M
Beta: -
Volume Today
584.90K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | 477.50K - | 16.18M 3,288.17% | 35.78M 121.16% | 37.47M 4.72% | |||
average payables | 451K - | 1.73M 284.37% | 5.08M 193.31% | 62.41M 1,127.52% | |||
average receivables | 3.03M - | 16.86M 456.72% | 41.45M 145.91% | 2.65M 93.60% | |||
book value per share | -0.83 - | -2.51 200.87% | 26.00 1,138.00% | 6.98 73.15% | 5.74 17.77% | 4.09 28.73% | |
capex per share | -0.12 - | -0.30 158.37% | -1.04 243.08% | -0.34 67.02% | -0.25 28.50% | ||
capex to depreciation | -8.64 - | -6.59 23.71% | -5.82 11.76% | -2.84 51.11% | -1.16 59.38% | ||
capex to operating cash flow | 0.42 - | 0.60 45.28% | 0.53 12.93% | 0.24 53.52% | 0.19 23.31% | ||
capex to revenue | -4.45 - | -0.69 84.50% | |||||
cash per share | 0.36 - | 0.68 90.68% | 19.94 2,843.65% | 4.59 76.99% | 3.37 26.49% | 2.44 27.54% | |
days of inventory on hand | 526.93 - | 168.59 68.01% | 148.23 12.08% | ||||
days payables outstanding | 43.04 - | 31.92 25.83% | 228.76 616.63% | ||||
days sales outstanding | 327.81 - | 138.40 57.78% | |||||
debt to assets | 0.17 - | 0.12 32.44% | 0.03 71.89% | 0.05 44.27% | 0.10 111.96% | 0.14 41.09% | |
debt to equity | -0.19 - | -0.08 55.95% | 0.04 143.66% | 0.05 46.20% | 0.12 125.04% | 0.18 51.67% | |
dividend yield | |||||||
earnings yield | -0.04 - | -0.13 234.79% | -0.58 360.77% | -0.15 74.29% | -0.53 254.52% | -0.91 71.33% | |
enterprise value | 7.13B - | 7.20B 1.02% | 408.29M 94.33% | 2.68B 557.48% | 486.82M 81.87% | 139.61M 71.32% | |
enterprise value over ebitda | -46.90 - | -22.92 51.13% | -0.25 98.89% | -3.83 1,404.36% | -0.65 83.11% | -0.28 57.08% | |
ev to operating cash flow | -67.13 - | -38.13 43.20% | -1.56 95.90% | -4.78 205.79% | -0.91 81.04% | ||
ev to sales | 87.17 - | 3.34 96.17% | 0.80 75.97% | ||||
free cash flow per share | -0.40 - | -0.81 101.49% | -3.02 274.84% | -1.75 42.14% | -1.55 11.04% | ||
free cash flow yield | -0.02 - | -0.04 96.71% | -0.14 232.78% | -0.16 16.94% | -0.40 150.77% | ||
graham net net | -1.38 - | -3.60 160.61% | 17.33 580.73% | 3.87 77.70% | 2.46 36.42% | 1.36 44.52% | |
graham number | 3.68 - | 11.84 221.21% | 86.87 633.98% | 16.06 81.52% | 16.33 1.69% | 13.11 19.72% | |
income quality | 0.39 - | 0.30 23.44% | 0.16 47.42% | 0.80 409.37% | 0.63 20.62% | ||
intangibles to total assets | 0.23 - | 0.23 0.00% | 0.21 11.91% | 0.26 27.66% | 0.32 22.24% | 0.33 2.71% | |
interest coverage | -38.48 - | -151.50 293.77% | -572.52 277.89% | -286.46 49.96% | -102.60 64.19% | ||
interest debt per share | 0.16 - | 0.21 28.45% | 0.94 348.20% | 0.37 60.27% | 0.70 86.14% | 0.74 5.53% | |
inventory turnover | 0.69 - | 2.17 212.55% | 2.46 13.73% | ||||
invested capital | -0.19 - | -0.08 55.95% | 0.04 143.66% | 0.05 46.20% | 0.12 125.04% | 0.18 51.67% | |
market cap | 7.21B - | 7.38B 2.43% | 2.92B 60.51% | 4.37B 49.96% | 1.59B 63.61% | 842.73M 47.03% | |
net current asset value | -482.71M - | -1.35B 179.59% | 2.30B 270.24% | 1.57B 31.70% | 1.05B 33.21% | 605.22M 42.26% | |
net debt to ebitda | 0.49 - | 0.56 14.26% | 1.56 177.66% | 2.41 54.00% | 1.47 39.05% | 1.40 4.69% | |
net income per share | -0.72 - | -2.49 242.93% | -12.90 419.00% | -1.64 87.28% | -2.06 25.76% | -1.87 9.57% | |
operating cash flow per share | -0.28 - | -0.50 77.85% | -1.98 294.01% | -1.40 29.05% | -1.31 6.77% | ||
payables turnover | 8.48 - | 11.43 34.83% | 1.60 86.05% | ||||
receivables turnover | 1.11 - | 2.64 136.85% | |||||
research and ddevelopement to revenue | 13.46 - | 2.80 79.20% | 2.38 15.00% | ||||
return on tangible assets | -1.05 - | -1.83 74.80% | -0.57 68.94% | -0.29 49.61% | -0.45 56.53% | -0.54 19.57% | |
revenue per share | 0.08 - | 0.36 361.17% | 0.42 18.91% | ||||
roe | 0.87 - | 0.99 13.98% | -0.50 150.00% | -0.24 52.62% | -0.36 52.94% | -0.46 26.88% | |
roic | 0.67 - | 0.36 46.33% | -0.13 134.93% | -0.24 91.47% | -0.26 7.79% | -0.29 10.34% | |
sales general and administrative to revenue | 2.57 - | 0.48 81.25% | 0.81 66.93% | ||||
shareholders equity per share | -0.83 - | -2.51 200.87% | 26.00 1,138.00% | 6.98 73.15% | 5.74 17.77% | 4.09 28.73% | |
stock based compensation to revenue | 2.90 - | 0.57 80.49% | 0.20 64.48% | ||||
tangible asset value | -393.20M - | -1.10B 179.57% | 2.65B 340.91% | 1.97B 25.68% | 1.45B 26.14% | 972.62M 33.09% | |
tangible book value per share | -1.05 - | -2.92 179.57% | 20.08 787.05% | 4.92 75.48% | 3.54 28.01% | 2.36 33.32% | |
working capital | -53.98M - | 138.52M 356.64% | 2.41B 1,640.01% | 1.70B 29.63% | 1.17B 30.76% | 803.01M 31.62% |
All numbers in (except ratios and percentages)